Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure

Status Withdrawn

Clinical Trial Summary

In the DAPA-HF trial, the use of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduced significantly the risk of worsening heart failure or death from cardiovascular causes compared to placebo among patients with heart failure (HF) and a reduced ejection fraction. This new drug offers a very potent and interesting therapeutic pathway since it reduces clinical congestion, it preserves glomerular renal function, does not appear to cause symptomatic clinical hypotension and improves symptoms and quality of life compared to placebo. Advanced heart failure patients with reduced ejection fraction represent a small and severe subgroup of heart failure of patients with frequent worsening heart failure events and high rates of death. The effect of dapagliflozin in this subgroup of patients was not assessed in the DAPA-HF study. The therapeutic profile of SGLT2 inhibitors appears to be of high interest, since this group of patients has a poor tolerance to usual heart failure drugs, frequent worsening renal function and congestive symptoms persistence with poor quality of life scores. Soluble urokinase-type plasminogen activator receptor (suPAR) is a signaling glycoprotein considered to be involved in the pathogenesis of kidney disease. It is associated with the risk of acute kidney injury in different clinical and experimental situation. It is also a new validated biomarker predictive of adverse clinical outcome in heart failure patients. This biomarker allows a better risk stratification in heart failure patients after adjustment for Nt-proBNP. As a useful biomarker implicated in both heart failure and acute kidney injury, suPAR seems to be an interesting biomarker to assess cardio-renal benefits of dapagliflozin. The aim of this study is to investigate if a treatment by dapagliflozin reduces significantly suPAR compared to placebo in a population of advanced heart failure patients, candidates to heart transplantation. The effect of dapagliflozin compared to placebo will also be assessed on other secondary heart failure outcomes in this patient population.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04782245
Study type	Interventional
Source	Hospices Civils de Lyon
Contact
Status	Withdrawn
Phase	Phase 2
Start date	September 2022
Completion date	April 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06063811` - Ventricular Tachycardia Ablation in LVAD Patients
Active, not recruiting	`NCT04351945` - Endocrine Changes and Their Correction in Heart and Lung Transplant Recipients and Donors
Recruiting	`NCT03966313` - Perioperative Modification of Hemostasis During Ventricular Assist Device Implantation
Recruiting	`NCT02592499` - Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure	N/A
Active, not recruiting	`NCT00490321` - VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy	Phase 3
Active, not recruiting	`NCT00483197` - VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Pivotal Trial	Phase 3
Completed	`NCT04543747` - Mechanical Circulatory Support Korea Post Market Surveillance Study (PMS)
Recruiting	`NCT04293575` - Transcatheter Mitral Valve Repair as Bridge Therapy to Heart Transplantation
Recruiting	`NCT04641416` - Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps
Completed	`NCT00490347` - VentrAssistTM LVAD as a Bridge to Cardiac Transplantation - Feasibility Trial	Phase 2
Suspended	`NCT04117295` - Carmat TAH Early Feasibility Study	N/A
Completed	`NCT05353816` - Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial	N/A
Completed	`NCT04480151` - ECLS Versus IMPELLA™ as Bridge to LVAD (ECI-BLAD)
Recruiting	`NCT04205760` - Preoperative Nutritional Optimization and Physical Exercise for Patients Scheduled for Elective Implantation for a Left-Ventricular Assist Device	Phase 3
Recruiting	`NCT06345521` - The Follow-up System of Pediatric Heart Failure and the Establishment of End-stage Heart Failure Registry
Recruiting	`NCT04768322` - LVAD Versus GDMT in Ambulatory Advanced Heart Failure Patients	N/A
Completed	`NCT02248974` - Development & Testing of a Decision Aid for LVAD Placement	N/A
Completed	`NCT06152562` - Evaluation of Platelet Therapy Response in Left Ventricular Assist Device Patients
Completed	`NCT05928273` - Corheart 6 LVAS LTFU	N/A
Recruiting	`NCT04951999` - AssocIation of PULSatility and Occurrence of Complications Related to Mechanically Assisted Circulatory Support	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List — ARCADIA-HF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms